Evidence map›Paper›PMID 38357830›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Integrated Multiomics Reveals Silencing of has_circ_0006646 Promotes TRIM21-Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis.

Xin Hu, Guanrong Chen, Yingchen Huang, Qiyang Cheng, Jianyong Zhuo, Renyi Su, Chiyu He, Yichao Wu, Zhikun Liu, Beng Yang and 9 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Xin HuZhejiang University School of Medicine, Hangzhou, 310058, China.
Guanrong ChenThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Yingchen HuangThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Qiyang ChengDepartment of Hepatobiliary Surgery, Beijing Chaoyang Hospital affiliated to Capital Medical University, Beijing, 100020, China.
Jianyong ZhuoKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Renyi SuZhejiang University School of Medicine, Hangzhou, 310058, China.
Chiyu HeZhejiang University School of Medicine, Hangzhou, 310058, China.
Yichao WuZhejiang University School of Medicine, Hangzhou, 310058, China.
Zhikun LiuKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Beng YangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
Shuai WangKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Lijun MengKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Shusen ZhengNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.
Di LuKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Qiang WeiKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Jiayin YangDepartment of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, 332001, China.
Xuyong WeiKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Ronggao ChenNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.
Xiao XuZhejiang University School of Medicine, Hangzhou, 310058, China.ORCID 0000-0002-2761-2811
Zhejiang Lab · CNBlood Center of Zhejiang Province · CNZhejiang Chinese Medical University · CNCapital Medical University · CNHangzhou First People's Hospital · CNSichuan University · CNZhejiang Shuren University · CN

Funding

Key Research & Development Plan of Zhejiang Province 2021C03118National Key Research and Development Program of China 2021YFA1100500Natural Science Foundation of Zhejiang Province LQ23H160030The Major Research Plan of the National Natural Science Foundation of China 92159202Youth Fund of the National Natural Science Foundation of China 82303379;81802889
6 · The paper itself

Abstract

Recent studies suggest that circular RNA (circRNA)-mediated post-translational modification of RNA-binding proteins (RBP) plays a pivotal role in metastasis of hepatocellular carcinoma (HCC). However, the specific mechanism and potential clinical therapeutic significance remain vague. This study attempts to profile the regulatory networks of circRNA and RBP using a multi-omics approach. Has_circ_0006646 (circ0006646) is an unreported circRNA in HCC and is associated with a poor prognosis. Silencing of circ0006646 significantly hinders metastasis in vivo. Mechanistically, circ0006646 prevents the interaction between nucleolin (NCL) and the E3 ligase tripartite motif-containing 21 to reduce the proteasome-mediated degradation of NCL via K48-linked polyubiquitylation. Furthermore, the change of NCL expression is proven to affect the phosphorylation levels of multiple proteins and inhibit p53 translation. Moreover, patient-derived tumor xenograft and lentivirus injection, which is conducted to simulate clinical treatment confirmed the potential therapeutic value. Overall, this study describes the integrated multi-omics landscape of circRNA-mediated NCL ubiquitination degradation in HCC metastasis and provides a novel therapeutic target.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA, CircularUbiquitinationAnimalsCell Line, TumorDisease Models, AnimalHumansMiceMultiomicsNeoplasm MetastasisNucleolinRNA-Binding ProteinsTripartite Motif ProteinsNucleolinRNA-Binding ProteinsRNA, CircularTripartite Motif ProteinsCircular RNAHepatocellular carcinomamulti‐omicsNucleolinubiquitination

Identifiers

PMID38357830
PMCPMC11040345
OpenAlexW4391838548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.